SymBio Pharmaceuticals

News

IR News

2026.04.01: Notice Regarding the Monthly Exercise Status of the 58th and 66th Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued through Third-Party Allotment
2026.04.01: コーポレート・ガバナンスに関する報告書 2026/04/01 (Japanese only)
2026.03.31: 事業計画及び成長可能性に関する事項(Japanese only)
2026.03.30: CRADA with NIH/NINDS for Multiple Sclerosis Extended for Three Years — Following Progressive Multifocal Leukoencephalopathy, SymBio to Further Advance Development in the Neurodegenerative Disease Field —
2026.03.27: Notice Regarding the Acceleration of Exercise of the 66th Stock Acquisition Rights Issued through Third-Party Allotment

Selection News

2026.03.27: 「動画で観るシンバイオ製薬」を更新しました。(Japanese only)

2026.03.27: 第21期定時株主総会の動画を掲載しました。(Japanese only)

2026.02.27: Information on Shareholders' Meeting: Updated the Page

2026.02.17: 株主通信「SymBio VISION vol.28」(Japanese only)

2026.02.13: 2025年12月期決算説明会の動画を掲載しました。(Japanese only)

2026.02.10: 決算説明会資料（2025年12月期）(Japanese only)

2025.08.18: Analyst Report[Full report] (Shared Research)

2025.08.12: 2025年12月期中間決算説明会の動画を掲載しました。(Japanese only)

2025.08.12: SymBio Announces Abstract on Brincidofovir for the Treatment of Malignant Brain Tumors (Glioblastoma) Accepted for Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting to be Held in November 2025

2025.08.05: 中間決算説明会資料（2025年12月期）(Japanese only)

2025.07.28: SymBio to Present Preclinical Data on Brincidofovir in Head and Neck Cancer at ESMO 2025 Congress

2025.06.30: SymBio Submits Clinical Trial Application for a Phase 3 Global Study Evaluating IV Brincidofovir for the Treatment of Adenovirus Infection after HSCT

2024.07.12: SymBio Pharmaceuticals Announces Publication of Research Showing Antiviral Drug Brincidofovir Inhibits Infectious Viral Production of Polyomavirus

2023.11.17: Notice of Relocation of Head Office

2023.11.06: SymBio To Present Positive Data from Ongoing Phase 2a Study of IV Brincidofovir in Adenovirus Infection in Oral Presentation at the 65th American Society of Hematology (ASH) Annual Meeting

2023.10.12: The Results of CRADA Study on Brincidofovir in Multiple Sclerosis Presented at the 9th Joint ECTRIMS-ACTRIMS Meeting

2023.07.20: Notice of Personnel Changes at SymBio Pharma USA, Inc.

2023.06.12: Presentation of the Results of Biomarker Research Predicting the Antitumor Effects of Brincidofovir at the 17th ICML

2023.05.29: IV Brincidofovir in Adenovirus Infection achieved POC in Phase 2 Clinical Trial

2023.04.24: SymBio enters into a CRADA to Assess Efficacy of Brincidofovir for Epstein-Barr Virus Associated Lymphoproliferative Disease

2023.03.22: Development of Brincidofovir for Multiple Sclerosis CRADA with the National Institute of Neurological Disorders and Stroke (NINDS)

SymBio in 2 minutes

動画で観るシンバイオ製薬(Japanese only)

Summary of Financial Statements for the Fiscal Year Ended December 31, 2025 [Japanese GAAP] (Consolidated)